Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits

By S. Ruehm, C. Corot, P. Vogt, S. Kolb, J. Debatin. Circulation, 2001

625 citations recorded by the source corpus.

Subfields: Biomaterials, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/873239030e5f09f538aa92ffd2123b46e1cee3fe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biomaterials

1. M. Gijs
2. A. C. Hunter

In Pulmonary and Respiratory Medicine

1. Erling Falk
2. Renu Virmani
3. M. Gijs
4. P. Ridker

Citations in the corpus

• Magnetic bead handling on-chip: new opportunities for analytical applications (2004, background): “The smaller particles, therefore, have a longer half-life time in the blood and are collected by certain types of cells in the lymph nodes and the bone marrow (Ruehm et al. 2001).”
• Nanomedicine: current status and future prospects (2005, background): “plaques (10, 11); this is a reflection of increased”
• From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. (2003, methodology): “Possible intravascular diagnostic techniques [34, 35] include thermography (measurement of plaque temperature) [36, 37], contrast-enhanced (CE) MRI [38, 39], fluorodeoxyglucose positron emission tomography [33, 40], and immunoscintigraphy [41].”
• Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging (2003, neutral): “2 ms; flip angle: 25 degrees; (2) T2*weighted (T2*w) gradient-echo (GE), TR/TE: 1 heart beat/20 ms; flip angle: 40 degrees; and (3) proton-density–weighted fast spinecho (PDw FSE), TR/TE: 2 to 3 beats/20 ms; echo train length: 5.”
• From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. (2003, methodology): “The only noninvasive options are presently MRI and possibly CT [34, 35, 59–62].”
• Iron oxide MR contrast agents for molecular and cellular imaging (2004, background): “and differentiate into macrophages, which can be visualized following USPIO administration.(60,61) Iron oxides”